Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Graft Versus Host Disease (GVHD) Pipeline Review 2016 - Therapeutics Analysis of 60 Companies & 83 Drug Profiles - Research and Markets

Research and Markets
Posted on: 21 Oct 16

Research and Markets has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016" report to their offering.

'Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies Universities.

'Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016'; Graft Versus Host Disease (GVHD) pipeline therapeutics constitutes close to 99 molecules. Out of which approximately 83 molecules are developed by Companies and remaining by the Universities/Institutes.

Graft Versus Host Disease (GVHD) Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, and diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment includes immunosuppressants.

It also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 23, 14, 33, 5 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 2, 10 and 1 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Graft Versus Host Disease Overview
  3. Therapeutics Development
  4. Pipeline Products for Graft Versus Host Disease - Overview
  5. Pipeline Products for Graft Versus Host Disease - Comparative Analysis
  6. Graft Versus Host Disease - Therapeutics under Development by Companies
  7. Graft Versus Host Disease - Therapeutics under Investigation by Universities/Institutes
  8. Graft Versus Host Disease Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Graft Versus Host Disease - Products under Development by Companies
  13. Graft Versus Host Disease - Products under Investigation by Universities/Institutes
  14. Graft Versus Host Disease - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Apceth GmbH & Co. KG
  • arGEN-X BV
  • Athersys, Inc.
  • Bellicum Pharmaceuticals, Inc.
  • Cytodyn Inc.
  • Dompe Farmaceutici S.p.A.
  • Dr. Falk Pharma GmbH
  • Escape Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fate Therapeutics, Inc.
  • Generon (Shanghai) Corporation Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Idera Pharmaceuticals, Inc.
  • ImmuNext, Inc.
  • Immunomedics, Inc.
  • Incyte Corporation
  • Mallinckrodt Plc
  • Medsenic
  • Mesoblast Limited
  • Millennium Pharmaceuticals Inc
  • Neopharm Ltd.
  • Nohla Therapeutics Inc.
  • Novartis AG
  • OncoImmune, Inc.
  • OSE Immunotherapeutics
  • Pharmicell Co., Ltd.
  • REGiMMUNE Corporation
  • Rigel Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.
  • Tobira Therapeutics, Inc.
  • Vault Pharma Inc.
  • Xenikos B.V.
  • ZIOPHARM Oncology, Inc.

For more information about this report visit

View source version on

Business Wire

Last updated on: 21/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.